Determination of 226Ra in 225Ac Active Pharmaceutical Ingredients by ICP-QQQ-MS
- 1NorthStar Medical Radioisotopes, LLC , 1800 Gateway Blvd , , ,
Abstract
Growing demand for 225Ac-radiopharmaceuticals in targeted α therapy (TAT) has led to the development of new and diverse 225Ac manufacturing processes. While this has augmented global 225Ac supply, it has also created a need for common analytical methods to ensure 225Ac active pharmaceutical ingredients (APIs) meet uniform expectations for safety and efficacy. A particular challenge is the measurement of long-lived radionuclidic impurities (e.g., 227Ac, 226Ra, or 229Th). Many of the common radiometric techniques for radiopharmaceutical quality control suffer from poor sensitivity and long measurement times when applied to long-lived radionuclides. Mass spectrometry presents an attractive alternative owing to greater sensitivity for long-lived radionuclides and faster sample measurement. Several new 225Ac manufacturing processes use the long-lived radionuclide 226Ra as a starting material. This work reports a method for the determination of 226Ra in 225Ac APIs using triple quadrupole inductively coupled plasma mass spectrometry (ICP-QQQ-MS). The sensitivity and interference formation characteristics of multiple instrument modes (STD, KED, O2) were evaluated to identify the best configuration for 226Ra determination. The polyatomic ion 225Ac1H+ was identified as an interference at m/z = 226 in both STD mode and KED mode, however, the use of O2 as a reaction gas effectively removed this interference. Thus, the measurement of 226Ra at m/z = 226 → 226 in O2 reaction mode provided the best combination of sensitivity and specificity. This methodology was evaluated against appropriate criteria for accuracy, precision, specificity, linearity, and lower range limits. Accuracy and precision were evaluated by spike recovery studies using 226Ra spiked 225Ac API solutions. Spike recoveries were 85–114% for samples with 0.0500 to 0.997 ng L –1 of 226Ra. Repeatability (n = 6, one analysis) and intermediate precision (n = 12, two analyses) were evaluated by replicate determinations of 226Ra spiked samples (0.499 ng L–1) giving RSDs of 3.8% and 6.5%, respectively. The instrumental detection limit and quantitation limit were estimated to be 0.010 ng L–1 (0.36 Bq L–1) and 0.030 ng L–1 (1.1 Bq L–1), respectively. The proposed methodology allows for rapid, sensitive determination of 226Ra in 225Ac APIs. Implementation into 225Ac manufacturing processes will support high standards of product safety and efficacy.
Related
- Undeclared Pharmacologically Active Ingredients in Over-the-Counter Skin Products
- Identifying the active ingredients of a behavioral activation-based digital single-session intervention
- Multimodal Evaluation of [225Ac]Ac-PSMA-617 Therapy in mCRPC: PET Based Total Tumor Volume, PSA Kinetics, and Blood Biomarkers
- Commercial Oat‐Based Cosmetic Ingredients Promote Antioxidant Capacity and Reduce Inflammatory Markers in Skin Cellular Stress Models: An Insight Into Molecular Mechanisms In Vitro
- Edible Mushroom Polysaccharides as Functional Food Ingredients for Metabolic Health: Preparation, Techno-Functional Behavior, and Requirements for Translation.
BibTeX
@article{baumeister2026determination,
title = {{Determination of 226Ra in 225Ac Active Pharmaceutical Ingredients by ICP-QQQ-MS}},
author = {Jakob E. Baumeister and Benjamin W. Puffer and Miguel Toro-González and Joshua B. McCormick and Cory A. Hawkins and Daniel J. De Vries},
journal = {ACS Omega},
year = {2026},
month = oct,
doi = {10.1021/acsomega.6c06224},
url = {https://pubs.acs.org/acsodf/article/doi/10.1021/acsomega.6c06224/5455272/Determination-of-226Ra-in-225Ac-Active},
note = {CC BY-NC-ND 4.0},
}
RIS
TY - JOUR
TI - Determination of 226Ra in 225Ac Active Pharmaceutical Ingredients by ICP-QQQ-MS
AU - Jakob E. Baumeister
AU - Benjamin W. Puffer
AU - Miguel Toro-González
AU - Joshua B. McCormick
AU - Cory A. Hawkins
AU - Daniel J. De Vries
PY - 2026
DA - 2026/10/21
JO - ACS Omega
DO - 10.1021/acsomega.6c06224
UR - https://pubs.acs.org/acsodf/article/doi/10.1021/acsomega.6c06224/5455272/Determination-of-226Ra-in-225Ac-Active
AB - Growing demand for 225Ac-radiopharmaceuticals in targeted α therapy (TAT) has led to the development of new and diverse 225Ac manufacturing processes. While this has augmented global 225Ac supply, it has also created a need for common analytical methods to ensure 225Ac active pharmaceutical ingredients (APIs) meet uniform expectations for safety and efficacy. A particular challenge is the measurement of long-lived radionuclidic impurities (e.g., 227Ac, 226Ra, or 229Th). Many of the common radiometric techniques for radiopharmaceutical quality control suffer from poor sensitivity and long measurement times when applied to long-lived radionuclides. Mass spectrometry presents an attractive alternative owing to greater sensitivity for long-lived radionuclides and faster sample measurement. Several new 225Ac manufacturing processes use the long-lived radionuclide 226Ra as a starting material. This work reports a method for the determination of 226Ra in 225Ac APIs using triple quadrupole inductively coupled plasma mass spectrometry (ICP-QQQ-MS). The sensitivity and interference formation characteristics of multiple instrument modes (STD, KED, O2) were evaluated to identify the best configuration for 226Ra determination. The polyatomic ion 225Ac1H+ was identified as an interference at m/z = 226 in both STD mode and KED mode, however, the use of O2 as a reaction gas effectively removed this interference. Thus, the measurement of 226Ra at m/z = 226 → 226 in O2 reaction mode provided the best combination of sensitivity and specificity. This methodology was evaluated against appropriate criteria for accuracy, precision, specificity, linearity, and lower range limits. Accuracy and precision were evaluated by spike recovery studies using 226Ra spiked 225Ac API solutions. Spike recoveries were 85–114% for samples with 0.0500 to 0.997 ng L –1 of 226Ra. Repeatability (n = 6, one analysis) and intermediate precision (n = 12, two analyses) were evaluated by replicate determinations of 226Ra spiked samples (0.499 ng L–1) giving RSDs of 3.8% and 6.5%, respectively. The instrumental detection limit and quantitation limit were estimated to be 0.010 ng L–1 (0.36 Bq L–1) and 0.030 ng L–1 (1.1 Bq L–1), respectively. The proposed methodology allows for rapid, sensitive determination of 226Ra in 225Ac APIs. Implementation into 225Ac manufacturing processes will support high standards of product safety and efficacy.
SN - 2470-1343
ER -